Navigation Links
HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems

CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three separate studies from its predictive human relevant systems at The Annual Society of Toxicology (SOT) meeting, being held in San Antonio, Texas, on March 10-14, 2013.  SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials. 


Each presentation provides evidence of HemoShear's ability to create physiologically accurate vascular or liver conditions that differentiate drug candidates and predict human response at in vivo-level drug doses.

Presentation Information:

DATE: March 12, 2013
ABSTRACT #: 1459
TITLE: Controlled Hemodynamics and Transport in Primary Hepatocytes Shift Induction and Toxic Responses to Drugs Closer to in vivo Concentrations
AUTHORS: Dash A, Deering T, Thomas J, Blackman BR and Wamhoff BR. 

DATE: March 12, 2013
ABSTRACT #: 1216
TITLE: Preclinical Profiling and Computational Differentiation of Human Vascular Response to 95 drugs Using NextGen RNASeq Transcriptomics
AUTHORS: Figler RA, Lawson MJ, Mackey AJ, Berzin EL, Anstey JC, Schoppee-Bortz PD, Tilghman RW, Blackman BR and Wamhoff BR.

DATE:  March 14, 2013
Late Breaking Abstract
TITLE: Human Primary Hepatocytes Under Controlled Hemodynamics Elicit Induction Responses to Drugs at Clinical Cmax Concentrations
AUTHORS: Dash A, Deering T, Marukian S, Thomas J, Blackman BR and Wamhoff BR.  HemoShear collaborator KaLy-Cell, located in Plobsheim France, provided high quality human hepatocytes and biological sample analysis for this program.  KaLy-Cell co-authors include Desbans C, Alexandre E and Richert L.

Drs. Ajit Dash and Brian Wamhoff from HemoShear will attend the SOT meeting.  For more information on the content of HemoShear's abstracts, interested parties may visit the SOT website at

About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  


Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
2. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
3. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
4. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
5. Masimo to Present at Raymond James 34th Annual Institutional Investors Conference
6. Express Scripts to Present at Upcoming Conferences
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. PAREXEL International To Present At Citi Global Healthcare Conference
9. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
10. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
11. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
(Date:11/26/2015)... San Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... accomplishment! On November 19, 2015, our surgeons performed their 6,000th free flap breast ... Ledoux , “We wake up every day excited to rebuild lives and it’s an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
(Date:11/26/2015)... ... ... Inc., developer and distributor of the world-class Asterisk based contact center software Q-Suite, announces ... new Q-Suite 6 platform is based on the latest Java Enterprise standards. By conforming ... of software for many key components of the suite. Much of the suite runs ...
(Date:11/25/2015)... ... November 25, 2015 , ... As part ... For Empowerment ™ attracts volunteers together who want to combine talents and resources ... key stakeholders in the process. The non-profit launched its first major fundraiser on ...
Breaking Medicine News(10 mins):